Jacobs Levy Equity Management
ORIC icon

Jacobs Levy Equity Management’s Oric Pharmaceuticals ORIC Stock Holding History

Jacobs Levy Equity Management’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-76,447
Closed -$776K – 1075
2025
Q2 		$776K Buy
+76,447
New +$513K ﹤0.01% 806
2022
Q4 		– Sell
-24,134
Closed -$77K – 1014
2022
Q3 		$77K Buy
+24,134
New +$96.6K ﹤0.01% 961

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Jacobs Levy Equity Management's ORIC Position: Q3 2025 in Review

Jacobs Levy Equity Management sold out of Oric Pharmaceuticals (ORIC) in Q3 2025, closing a stake of 76,447 shares — an estimated $776K sold.

Jacobs Levy Equity Management first reported a position in ORIC in Q3 2022 and held it in 2 quarters. The position peaked at $776K in Q2 2025. 152 funds tracked by Wall St. Rank hold ORIC as of Q3 2025.

  • Jacobs Levy Equity Management reported no remaining Oric Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 76,447 Oric Pharmaceuticals shares in Q3 2025, an estimated $776K.
  • Jacobs Levy Equity Management first reported a position in Oric Pharmaceuticals in Q3 2022 and held it in 2 quarters.
  • Jacobs Levy Equity Management's Oric Pharmaceuticals position peaked at $776K in Q2 2025.
  • 152 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q3 2025.

Based on Jacobs Levy Equity Management's 13F filing for Q3 2025, filed 17 Nov 2025.